Intelsat Supports Programmers With Cloud Connect Media
12.4.2022 16:00:00 EEST | Business Wire | Press release
Intelsat — operator of the world’s largest integrated satellite and terrestrial network and a leading provider of inflight connectivity (IFC) — today announced its latest service offering: Cloud Connect Media, a connectivity solution that provides programmers with secure access between the IntelsatOne Media Network and Amazon Web Services (AWS).
Cloud Connect Media is designed to provide content providers with a private, dedicated secure gateway between AWS and the Intelsat global media distribution network. Intelsat is an AWS Select Partner in the AWS Partner Network (APN).
This collaboration can provide Intelsat media customers a more efficient way to connect to their playout, video editing, and additional resources they use in the cloud while still accessing the IntelsatOne media network for centralized distribution and managed services, including uplink and/or downlink to key satellites and teleports, colocation, and much more.
C-SPAN, the nonprofit, public affairs network providing Americans with unfiltered access to federal government proceedings, will be the first Intelsat customer to use Cloud Connect Media to add resiliency and reliability to their linear workflows. C-SPAN and Intelsat have been longstanding partners driving innovation in the media industry, and this trend continues with Cloud Connect Media.
“Intelsat's rollout of Cloud Connect Media helps complete C-SPAN’s transition to a total cloud configuration by providing a fast and reliable path from our uplink location directly to Amazon Web Services, with the most up-to-date connectivity available,” said Roxane Kerr, vice president of Technology for C-SPAN.
“The ability to send and receive media content securely from the cloud, while maintaining broadcast-grade distribution reliability, has become a focus for many of our media customers,” said Bill O’Hara, vice president and general manager of Media Business at Intelsat. “Cloud Connect Media uses AWS to help our customers access their cloud services while still being able to utilize the industry-leading Intelsat network and our full suite of media managed services for regional and global video distribution.”
In addition to advancing media services, Intelsat customers using enterprise and commercial aviation connectivity services who also require dedicated secure connectivity to their cloud-based services will be able to take advantage of AWS Direct Connect.
“AWS Direct Connect can support Intelsat’s mission with a low latency, secure, and private connection to the global AWS network,” said Clint Crosier, director, Aerospace and Satellite at AWS. “The speed and agility of AWS are well suited to help Intelsat meet customer expectations for rapid, reliable global connectivity and communication.”
Cloud Connect Media expands the capabilities of Intelsat’s Cloud Connect, launched in 2020 with secure cloud connectivity available to customers of the global FlexEnterprise network. As organizations continue to integrate cloud-based services into their operations, the Cloud Connect portfolio will aggregate the capabilities of cloud partners and Intelsat’s global networks to enable new services and extend the benefits and reach of the cloud to locations around the globe.
Cloud Connect Media is currently available in the United States and Europe.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world’s most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world’s first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and “Imagine Here,” with us, at Intelsat.com.
Follow Us on Social Media:
Twitter | LinkedIn | Facebook | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005361/en/
Contact information
Media:
Melissa Longo
melissa.longo@intelsat.com
+1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom